Northern Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $284M | Buy |
858,120
+378
| +0% | +$129K | 0.04% | 391 |
|
|
2025
Q4 | $341M | Buy |
857,742
+24,591
| +3% | +$10.9M | 0.04% | 349 |
|
|
2025
Q3 | $380M | Buy |
833,151
+1,374
| +0.2% | +$559K | 0.05% | 328 |
|
|
2025
Q2 | $271M | Sell |
831,777
-33,243
| -4% | -$9.2M | 0.04% | 394 |
|
|
2025
Q1 | $234M | Sell |
865,020
-13,840
| -2% | -$3.56M | 0.03% | 427 |
|
|
2024
Q4 | $207M | Buy |
878,860
+143,941
| +20% | +$37.9M | 0.03% | 465 |
|
|
2024
Q3 | $202M | Sell |
734,919
-45,916
| -6% | -$12M | 0.03% | 429 |
|
|
2024
Q2 | $190M | Buy |
780,835
+41,251
| +6% | +$6.51M | 0.03% | 439 |
|
|
2024
Q1 | $111M | Sell |
739,584
-24,936
| -3% | -$4.16M | 0.02% | 586 |
|
|
2023
Q4 | $146M | Sell |
764,520
-33,180
| -4% | -$5.65M | 0.03% | 498 |
|
|
2023
Q3 | $141M | Buy |
797,700
+25,230
| +3% | +$4.81M | 0.03% | 503 |
|
|
2023
Q2 | $147M | Buy |
772,470
+10,886
| +1% | +$2.16M | 0.03% | 490 |
|
|
2023
Q1 | $153M | Buy |
761,584
+12,045
| +2% | +$2.53M | 0.03% | 470 |
|
|
2022
Q4 | $178M | Buy |
749,539
+15,547
| +2% | +$3.32M | 0.04% | 432 |
|
|
2022
Q3 | $147M | Sell |
733,992
-2,945
| -0.4% | -$562K | 0.03% | 439 |
|
|
2022
Q2 | $107M | Sell |
736,937
-26,403
| -3% | -$3.75M | 0.02% | 544 |
|
|
2022
Q1 | $125M | Sell |
763,340
-6,073
| -0.8% | -$925K | 0.02% | 573 |
|
|
2021
Q4 | $130M | Sell |
769,413
-9,708
| -1% | -$1.8M | 0.02% | 578 |
|
|
2021
Q3 | $147M | Buy |
779,121
+70,615
| +10% | +$13.2M | 0.03% | 530 |
|
|
2021
Q2 | $120M | Sell |
708,506
-41,706
| -6% | -$6.11M | 0.02% | 597 |
|
|
2021
Q1 | $106M | Buy |
750,212
+7,442
| +1% | +$1.12M | 0.02% | 644 |
|
|
2020
Q4 | $96.5M | Sell |
742,770
-9,628
| -1% | -$1.29M | 0.02% | 656 |
|
|
2020
Q3 | $110M | Sell |
752,398
-22,641
| -3% | -$3.22M | 0.02% | 528 |
|
|
2020
Q2 | $115M | Buy |
775,039
+78,943
| +11% | +$10.6M | 0.03% | 499 |
|
|
2020
Q1 | $75.8M | Buy |
696,096
+29,075
| +4% | +$3.36M | 0.02% | 581 |
|
|
2019
Q4 | $76.8M | Buy |
667,021
+483
| +0.1% | +$48.2K | 0.02% | 711 |
|
|
2019
Q3 | $53.6M | Buy |
666,538
+96,655
| +17% | +$7.65M | 0.01% | 919 |
|
|
2019
Q2 | $41.4M | Buy |
569,883
+11,578
| +2% | +$888K | 0.01% | 1145 |
|
|
2019
Q1 | $52.2M | Buy |
558,305
+26,657
| +5% | +$2.23M | 0.01% | 937 |
|
|
2018
Q4 | $38.8M | Buy |
531,648
+37,136
| +8% | +$2.86M | 0.01% | 1048 |
|
|
2018
Q3 | $43.3M | Buy |
494,512
+1,744
| +0.4% | +$175K | 0.01% | 1130 |
|
|
2018
Q2 | $48.5M | Buy |
492,768
+20,992
| +4% | +$2.08M | 0.01% | 1034 |
|
|
2018
Q1 | $56.2M | Sell |
471,776
-2,833
| -0.6% | -$365K | 0.01% | 898 |
|
|
2017
Q4 | $60.3M | Buy |
474,609
+97,881
| +26% | +$12.3M | 0.02% | 839 |
|
|
2017
Q3 | $44.3M | Sell |
376,728
-292
| -0.1% | -$24.9K | 0.01% | 1057 |
|
|
2017
Q2 | $30.1M | Buy |
377,020
+17,862
| +5% | +$1.14M | 0.01% | 1368 |
|
|
2017
Q1 | $18.4M | Buy |
359,158
+13,199
| +4% | +$610K | 0.01% | 1683 |
|
|
2016
Q4 | $13M | Sell |
345,959
-26,343
| -7% | -$1.1M | ﹤0.01% | 1924 |
|
|
2016
Q3 | $25.2M | Buy |
372,302
+7,927
| +2% | +$559K | 0.01% | 1393 |
|
|
2016
Q2 | $20.2M | Buy |
364,375
+12,927
| +4% | +$814K | 0.01% | 1523 |
|
|
2016
Q1 | $22.2M | Buy |
351,448
+11,904
| +4% | +$791K | 0.01% | 1416 |
|
|
2015
Q4 | $32M | Sell |
339,544
-66,757
| -16% | -$6.19M | 0.01% | 1123 |
|
|
2015
Q3 | $32.6M | Sell |
406,301
-18,932
| -4% | -$2.1M | 0.01% | 1103 |
|
|
2015
Q2 | $51M | Buy |
425,233
+103,393
| +32% | +$12.4M | 0.02% | 838 |
|
|
2015
Q1 | $33.6M | Buy |
321,840
+45,575
| +16% | +$4.62M | 0.01% | 1174 |
|
|
2014
Q4 | $26.8M | Sell |
276,265
-88
| -0% | -$8.15K | 0.01% | 1316 |
|
|
2014
Q3 | $21.6M | Sell |
276,353
-387,344
| -58% | -$25M | 0.01% | 1453 |
|
|
2014
Q2 | $41.9M | Sell |
663,697
-103,447
| -13% | -$6.15M | 0.01% | 926 |
|
|
2014
Q1 | $51.5M | Sell |
767,144
-53,641
| -7% | -$4.15M | 0.02% | 801 |
|
|
2013
Q4 | $52.8M | Buy |
820,785
+15,307
| +2% | +$913K | 0.02% | 740 |
|
|
2013
Q3 | $51.6M | Buy |
805,478
+16,023
| +2% | +$799K | 0.02% | 691 |
|
|
2013
Q2 | $24.5M | Buy |
+789,455
| New | +$21M | 0.01% | 1212 |
|
Other funds holding ALNY
VPM
VCM
Northern Trust's ALNY Position: Q1 2026 in Review
Northern Trust increased its Alnylam Pharmaceuticals (ALNY) stake by 0.04% in Q1 2026, buying an estimated $129K and bringing the position to 858,120 shares worth $284M. The position accounts for 0.04% of the portfolio, ranked #391.
Northern Trust first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $380M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Northern Trust held 858,120 shares of Alnylam Pharmaceuticals worth $284M as of Q1 2026.
- Northern Trust bought 378 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $129K.
- Alnylam Pharmaceuticals made up 0.04% of Northern Trust's portfolio in Q1 2026, its #391 holding.
- Northern Trust first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Northern Trust's Alnylam Pharmaceuticals position peaked at $380M in Q3 2025.
- 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.